Skip to main
ABBV

AbbVie (ABBV) Stock Forecast & Price Target

AbbVie (ABBV) Analyst Ratings

Based on 22 analyst ratings
Buy
Strong Buy 32%
Buy 55%
Hold 14%
Sell 0%
Strong Sell 0%

Bulls say

AbbVie is supported by durable growth in immunology, where Skyrizi and Rinvoq continue to post strong prescription gains and help offset the legacy Humira decline, while the company’s 2026 guidance and EPS outlook reflect solid operating momentum. It also benefits from a broadening portfolio in neuroscience and oncology, with Vyalev showing rapid TRx growth and added scale from the 2020 Allergan deal plus the 2024 Cerevel and ImmunoGen acquisitions, which reduce concentration risk and deepen the pipeline. With strong cash generation, a roughly 3% dividend, and valuation that appears attractive relative to its growth profile, the company presents a compelling fundamental case.

Bears say

AbbVie is exposed to a tougher fundamental setup as government pricing pressure and IRA headwinds are eroding oncology net pricing, while Imbruvica is expected to decline 20% in net pricing and 14% in TRx, more than offsetting Venclexta’s 8% sales growth despite 30% TRx growth. The company’s immunology base is still concentrated in Skyrizi and Rinvoq, but increasing competition, low single-digit price headwinds, and patent risk threaten durability just as 2Q26 revenue is expected at $16.65bn versus $16.76bn consensus and EPS is near the low end of guidance. Added acquisition and integration costs, including $3.7bn in upfront charges in nine months of 2025, plus product-liability and antitrust overhangs, reinforce the view that margins and valuation face sustained pressure.

AbbVie (ABBV) has been analyzed by 22 analysts, with a consensus rating of Buy. 32% of analysts recommend a Strong Buy, 55% recommend Buy, 14% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of AbbVie and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About AbbVie (ABBV) Forecast

Analysts have given AbbVie (ABBV) a Buy based on their latest research and market trends.

According to 22 analysts, AbbVie (ABBV) has a Buy consensus rating as of Oct 9, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $283.82, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $283.82, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

AbbVie (ABBV)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.